WO2007058581A1 - Nouveaux derives de 2-aminopyrimidine derivatives et leur utilisation - Google Patents

Nouveaux derives de 2-aminopyrimidine derivatives et leur utilisation Download PDF

Info

Publication number
WO2007058581A1
WO2007058581A1 PCT/SE2006/001281 SE2006001281W WO2007058581A1 WO 2007058581 A1 WO2007058581 A1 WO 2007058581A1 SE 2006001281 W SE2006001281 W SE 2006001281W WO 2007058581 A1 WO2007058581 A1 WO 2007058581A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
aryl
heteroaryl
compound
haloalkyl
Prior art date
Application number
PCT/SE2006/001281
Other languages
English (en)
Inventor
Jeffrey Albert
Gianni Chessari
Phil Edwards
Original Assignee
Astrazeneca Ab
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astex Therapeutics Ltd filed Critical Astrazeneca Ab
Priority to US12/093,646 priority Critical patent/US20080255167A1/en
Priority to EP06813004A priority patent/EP1951681A4/fr
Priority to JP2008541108A priority patent/JP2009515950A/ja
Publication of WO2007058581A1 publication Critical patent/WO2007058581A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Definitions

  • the present invention relates to novel compounds, their pharmaceutical compositions.
  • the present invention relates to therapeutic methods for the treatment and/or prevention of A ⁇ -related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
  • a ⁇ -related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease
  • BACE was found to be a pepsin-like aspartic proteinase, the mature enzyme consisting of the N-terminal catalytic domain, a transmembrane domain, and a small cytoplasmic domain.
  • BACE has an optimum activity at pH 4.0-5.0 (Vassar et al, 1999)) and is inhibited weakly by standard pepsin inhibitors such as pepstatin. It has been shown that the catalytic domain minus the transmembrane and cytoplasmic domain has activity against substrate peptides (Lin et al, 2000).
  • BACE is a membrane bound type 1 protein that is synthesized as a partially active proenzyme, and is abundantly expressed in brain tissue.
  • a ⁇ amyloid- ⁇ -protein
  • a ⁇ or amyloid- ⁇ -protein is the major constituent of the brain plaques which are characteristic of Alzheimer's disease (De Strooper et al, 1999).
  • a ⁇ is a 39-42 residue peptide formed by the specific cleavage of a class I transmembrane protein called APP, or amyloid precursor protein.
  • a ⁇ -secretase activity cleaves this protein between residues Met671 and Asp672 (numbering of 770aa isoform of APP) to form the N-terminus of A ⁇ .
  • a second cleavage of the peptide is associated with ⁇ -secretase to form the C-terminus of the A ⁇ peptide.
  • Alzheimer's disease is estimated to afflict more than 20 million people worldwide and is believed to be the most common form of dementia.
  • Alzheimer's disease is a progressive dementia in which massive deposits of aggregated protein breakdown products - amyloid plaques and neurofibrillary tangles accumulate in the brain. The amyloid plaques are thought to be responsible for the mental decline seen in Alzheimer's patients.
  • Alzheimer's disease increases with age, and as the aging population of the developed world increases, this disease becomes a greater and greater problem.
  • this disease becomes a greater and greater problem.
  • any individuals possessing the double mutation of APP known as the Swedish mutation (in which the mutated APP forms a considerably improved substrate for BACE) have a much greater chance of developing AD, and also of developing it at an early age (see also US 6,245,964 and US 5,877,399 pertaining to transgenic rodents comprising APP-Swedish). Consequently, there is also a strong need for developing a compound that can be used in a prophylactic fashion for these individuals.
  • telome 21 The gene encoding APP is found on chromosome 21, which is also the chromosome found as an extra copy in Down's syndrome. Down's syndrome patients tend to acquire
  • Alzheimer's disease at an early age with almost all those over 40 years of age showing Alzheimer's-type pathology (Oyama et al., 1994). This is thought to be due to the extra copy of the APP gene found in these patients, which leads to overexpression of APP and therefore to increased levels of APP ⁇ causing the high prevalence of Alzheimer's disease seen in this population.
  • inhibitors of BACE could be useful in reducing Alzheimer's-type pathology in Down's syndrome patients.
  • Drugs that reduce or block BACE activity should therefore reduce A ⁇ levels and levels of fragments of A ⁇ in the brain, or elsewhere where A ⁇ or fragments thereof deposit, and thus slow the formation of amyloid plaques and the progression of AD or other maladies involving deposition of A ⁇ or fragments thereof (Yankner, 1996; De Strooper and Konig, 1999).
  • BACE is therefore an important candidate for the development of drugs as a treatment and/or prophylaxis of A ⁇ -related pathologies such as Downs syndrome and ⁇ - amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
  • a ⁇ -related pathologies such as Downs syndrome and ⁇ - amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms
  • the compounds of the present invention show improved properties compared to the potential inhibitors known in the art, e.g. improved hERG selectivity.
  • s R 1 is H, Si(Ci -10 aUcyl) 3 , CN, NO 2 , OR a , SR a , OC(O)R a , OC(O)OR b , OC(O)NR°R d ,
  • R 3 is C 1-6 alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein each of the Ci -6 alkyl, aryl, heteroaryl, 5 cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4 or 5 R 4 ;
  • R is each, independently, halo, C 1-4 alkyl, C 1-4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN 5 NO 2 , OR a' , SR a> 5 C(O)R b> , C(0)NR c R d> , C(O)OR a> , OC(
  • L is C 2-10 alkenylenyl, C 2-10 alkynylenyl, (CR s R 6 ) q , (CR 5 R 6 ) ql CO(CR 5 R 6 ) q2 or
  • Cy 1 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, each optionally substituted with 1,
  • a 1 and A 2 are each, independently, halo, CN, NO 2 , OR a , SR a , C(O)R b , C(0)NR c R d , C(O)OR ⁇ 0C(0)R b , 0C(0)NR c R d , NR c R d , NR°C(O)R d , NR c C(O)OR a , , NR°S(O)R b , NR°S(O) 2 R b , S(O)R b , S(0)NR c R d , S(O) 2 R b , S(O) 2 NR c R d , C 1-4 alkoxy, d -4 haloalkoxy, amino, C 1-4 alkylamino, C 2-8 dialkylamino, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, ary
  • R c and R d are each, independently, H, C 1-10 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein the C 1-10 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 haloalkyl, aryl, arylalkyl, heteroaryl, hetero
  • R c and R d are each, independently, H, C 1-10 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein the C 1-10 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, C 1-6 alkyl, C 1-6 haloalkyl, Ci -6 haloalkyl, aryl, arylalkyl, heteroaryl, hetero
  • R e is H, C 1-4 alkyl, C M haloalkyl, C 2-4 alkenyl, C 2-4 alkynyl, or CO-(C 1-4 alkyl); q is 1, 2, 3, 4, 5 or 6; ql is O, 1, 2 or 3; and q2 is 0, 1, 2 or 3.
  • R 1 is H, Ci -6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein the Ci -6 alkyl, Ci -6 haloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4 or 5 R 4 .
  • R 1 is H, C 1-6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein each of the C 1-6 alkyl, Ci -6 haloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted by I 5 2 or 3 substituents independently selected from halo, CN, OH, Ci -6 alkoxy, Ci -6 haloalkoxy, Ci -6 haloalkyl, Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl.
  • R 1 is H, Ci -6 alkyl or C 1-6 haloalkyl, wherein the Ci -6 alkyl is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, OH, Ci -6 alkoxy, Ci -6 haloalkoxy, Ci -6 haloalkyl, Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl.
  • R 1 is H, Ci -6 alkyl or Q -6 haloalkyl.
  • R 1 is H.
  • R 2 is halo
  • R 2 is chloro
  • R 2 is OR 3 .
  • R 2 is OR 3 ; and R 3 is Ci -6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein each of the Ci -6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4 or 5 R 4 .
  • R 2 is OR 3 ; and R 3 is C 1-6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein each of the C 1-6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, C 1-4 alkyl, C 1-4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, aryloxy, cycloalkyloxy, heteroaryloxy and heterocycloalkyloxy.
  • R 4 is each, independently, halo, Ci -4 alkyl, C 1-4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, aryloxy, cycloalkyloxy, heteroaryloxy or heterocycloalkyloxy.
  • L is C 2- io alkenylenyl, C 2-10 alkynylenyl or (CR 5 R 6 ) q .
  • L is (CR 5 R 6 ) q .
  • L is (CR 5 R 6 ) q ; and R 5 and R 6 are each, independently, H, halo, Ci -4 alkyl, C 1-4 haloalkyl CN, NO 2 , OH, Q -4 alkoxy.
  • Q is aryl or heteroaryl, each substituted by 1 Cy 1 and optionally substituted by 1 , 2, 3, or 4 A 1 .
  • Q is aryl or heteroaryl, each substituted by 1 Cy 1 and optionally substituted by I 3 2, 3, or 4 A 1 ; and Cy 1 is aryl or heteroaryl, each optionally substituted with 1, 2, 3, 4 or 5 A 2 .
  • Q is aryl substituted by 1 Cy 1 and optionally substituted by 1, 2, 3, or 4 A 1 ; and Cy 1 is aryl or heteroaryl, each optionally substituted with 1, 2, 3, 4 or 5 A 2 .
  • Q is phenyl substituted by 1 Cy 1 and optionally substituted by 1, 2, 3, or 4 A 1 ; and Cy 1 is aryl or heteroaryl, each optionally substituted with 1 , 2, 3, 4 or 5 A 2 .
  • Q is phenyl substituted by 1 Cy 1 at a meta-position and optionally substituted by I 5 2, 3, or 4 A 1 ; and Cy 1 is aryl or heteroaryl, each optionally substituted with 1, 2, 3, 4 or 5 A
  • R 1 is H, C 1-6 alkyl or C 1-6 haloalkyl
  • R 2 is chloro or OR 3
  • R 3 is C 1-6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein each of the C 1-6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, C 1-4 alkyl, C 1-4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, aryloxy, cycloalkyloxy, heteroaryloxy and heterocycloalkyloxy;
  • L is (CR 5 R 6 ) q ;
  • R 5 and R 6 are each, independently, H, halo, C 1-4 alkyl, Ci
  • q is 2.
  • Q is phenyl substituted by 1 Cy 1 and optionally substituted by 1, 2, 3, or 4 A 1 ; and Cy 1 is aryl or heteroaryl, each optionally substituted with 1 , 2, 3, 4 or 5 A 2 .
  • q is 2 and Cy 1 is aryl or heteroaryl, each optionally substituted with 1, 2, 3, 4 or 5 A 2 .
  • R 1 is H, C 1-6 alkyl or C ⁇ ghaloalkyl;
  • R 2 is chloro or OR 3 ; and
  • R 3 is Ci- 6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein each of the C 1-6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, C 1-4 alkyl, C 1-4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, aryloxy, cycloalkyloxy, heteroaryloxy and heterocycloalkyloxy.
  • compositions comprising a compound of any of the formulas described herein, or a pharmaceutically acceptable salt, tautomer or in vzv ⁇ -hydrolysable precursor thereof, and at least one pharmaceutically acceptable carrier, diluent or excipient.
  • the present invention further provides methods of modulating activity of BACE comprising contacting the BACE with a compound of any of the formulas described herein, or a pharmaceutically acceptable salt, tautomer or in vzvo-hydrolysable precursor thereof.
  • the present invention further provides methods of treating or preventing an A ⁇ -related pathology in a patient, comprising administering to the patient a therapeutically effective amount of a compound of any of the formulas described herein, or a pharmaceutically acceptable salt, tautomer or in vzv ⁇ -hydrolysable precursor thereof.
  • the present invention further provides a compound of any of the formulas described herein, or a pharmaceutically acceptable salt, tautomer or in vz ' vo-hydrolysable precursor thereof, described herein for use as a medicament.
  • the present invention further provides a compound of any of the formulas described herein, or a pharmaceutically acceptable salt, tautomer or in vrvo-hydrolysable precursor thereof, described herein for the manufacture of a medicament.
  • R 1 is H, Si(C 1-10 alkyl) 3> CN, NO 2 , OR a , SR a , OC(O)R a , OC(O)OR b , OC(O)NR c R d , C(O)R a , C(O)OR b , C(O)NR c R d , NR c R d , NR 0 C(O)R 3 , NR c C(O)OR b , NR c S(O) 2 R b , S(O)R a , S(O)NR c R d , S(O) 2 R a , S(O) 2 NR c R d , C 1-I0 alkyl, C 1-I0 haloalkyl, C 2-10 alkenyl, C 2-1 O alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, C 1-I0 al
  • R 1 is H, Ci- 6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein the C 1-6 alkyl, C 1-6 haloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4 or 5 R 4 .
  • R 1 is H, C 1-6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein each of the C 1-6 alkyl, C 1-6 haloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted by 1, 2 or 3 substiruents independently selected from halo, CN, OH, Ci -6 alkoxy, Ci-ghaloalkoxy, C 1-6 haloalkyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl.
  • R 1 is H, C 1-6 alkyl or C 1-6 haloalkyl, wherein the Ci -6 alkyl is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, OH, C 1-6 alkoxy, C 1-6 haloalkoxy, Ci -6 haloalkyl, Q- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, aryl, cycloalkyl, heteroaryl and heterocycloalkyl.
  • R 1 is H, Ci -6 alkyl or Ci -6 haloalkyl.
  • R is H.
  • R 1 is H, Ci -6 alkyl or Ci -6 haloalkyl.
  • R 2 is halo or OR . In some embodiments, R 2 is halo. In some embodiments, R 2 is chloro. In some embodiments, R 2 is OR 3 . In some embodiments, R 2 is chloro or OR 3 .
  • R 3 is C 1-6 alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, or any subgroup thereof, wherein each of the C 1-6 alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4 or 5 R 4 , or any subgroup thereof.
  • R 3 is Ci -6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein each of the C 1 . e alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4 or 5 R 4 .
  • R 3 is Ci -6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein each of the Ci -6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, Ci -4 alkyl, Ci -4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, aryloxy, cycloalkyloxy, heteroaryloxy and heterocycloalkyloxy.
  • R 3 is Ci -6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein each of the Ci -6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted by 1 , 2, 3, 4 or 5 substituents independently selected from halo, Q -4 alkyl, Ci -4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, aryloxy, cycloalkyloxy, heteroaryloxy and heterocycloalkyloxy.
  • R 4 is each, independently, halo, Ci -4 alkyl, Ci -4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO 2 , OR a' , SR a' 5 C(O)R b' , C(0)NR c R d' , C(O)OR a' , OC(O)R b> , OC(O)NR c' R d> , NR c R d> , NR C C(O)R d' , NR C C(O)OR 3' ,
  • R 4 is each, independently, halo, Ci -4 alkyl, Ci -4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, aryloxy, cycloalkyloxy, heteroaryloxy or heterocycloalkyloxy.
  • R 5 and R 6 are each, independently, H, halo, Ci -4 alkyl, C 1-4 baloalkyl, atyl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO 2 , OR a' , SR a> , C(O)R b' , C(0)NR° ' R d> , C(O)OR 3' , OC(O)R b> , 0C(0)NR c> R d' , NR c R d' , NR° ' C(O)R d> , NR c C(O)OR a' , NR c' S(O) 2 R b' , S(O)R b' , S(O)NR c' R d> , S(O) 2 R b' , or S(O) 2 NR 0> R d' , or any subgroup thereof.
  • R 5 is independently, H, hal
  • Q is aryl, cycloalkyl, heteroaryl or heterocycloalkyl, or any subgroup thereof, each substituted by 1 Cy 1 and optionally substituted by 1, 2, 3, or 4 A 1 , or any subgroup thereof.
  • Q is aryl or heteroaryl, each substituted by 1 Cy 1 and optionally substituted by 1, 2, 3, or 4 A 1 .
  • Q is aryl substituted by 1 Cy 1 and optionally substituted by 1, 2, 3, or 4 A 1 .
  • Q is phenyl substituted by 1 Cy 1 and optionally substituted by 1, 2, 3, or 4 A 1 .
  • Q is phenyl substituted by 1 Cy 1 at a meta-position and optionally substituted by 1, 2, 3, or 4 A 1 .
  • L is C 2-1O alkenylenyl, C 2-I o alkynylenyl, (CR 5 R 6 ) q ,
  • L is C2-10 alkenylenyl, C2-10 alkynylenyl or (CR 5 R 6 ) q . In some embodiments, L is (CR 5 R 6 ) q . In some embodiments, L is (CR 5 R 6 ) 2 .
  • Cy 1 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, or any subgroup thereof, each optionally substituted with 1, 2, 3, 4 or 5 A 2 , or any subgroup thereof. In some embodiments, Cy 1 is aryl or heteroaryl, each optionally substituted with 1, 2, 3, 4 or 5 A 2 .
  • a 1 and A 2 are each, independently, halo, CN, NO 2 , OR a , SR a , C(O)R b , C(O)NR c R d , C(O)OR a , OC(O)R b , OC(O)NR c R d , NR c R d , NR c C(O)R d , NR c C(O)OR a , NR°S(O)R b , NR c S(O) 2 R b , S(O)R b , S(O)NR c R d , S(O) 2 R b , S(O) 2 NR c R d , C 1-4 alkoxy, amino, C 1-4 alkylamino, C 2-8 dialkylamino, Q- ⁇ alkyl, C 2-6 alkenyl, C 2-6 alkynyl, arylalkyl,
  • R a and R a' are each, independently, H, C 1-6 alkyl, C 1-6 haloalkyl, C 2- 6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, or any subgroup thereof, wherein the C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, C 1-6 alkyl, C 1-6 haloalkyl, aryl, arylalkyl, heteroaryl,
  • R b and R b are each, independently, H, C 1-6 alkyl, C 1-6 haloalkyl, C 2- 6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, or any subgroup thereof, wherein the Ci- 6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, C 1-6 alkyl, C 1-6 haloalkyl, Ci -6 haloalkyl, aryl, ary
  • R c and R d are each, independently, H, C 1-10 alkyl, Ci -6 haloalkyl, C 2- 6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, or any subgroup thereof, wherein the C 1-10 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Ci -6 alkyl, Ci -6 haloalkyl, C 1-6 haloalkyl, aryl, ary
  • R° and R d together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group, or any subgroup thereof.
  • R c and R d are each, independently, H, Ci -10 alkyl, Ci -6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, or any subgroup thereof, wherein the C 1- I 0 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with OH, amino, halo, Ci -6 alkyl, Ci -6 haloalkyl, Ci -6 haloalkyl, aryl,
  • R c and R d together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group, or any subgroup thereof.
  • R e is H, Ci -4 alkyl, Ci -4 haloalkyl, C 2-4 alkenyl, C 2-4 alkynyl, or CO- (Ci -4 alkyl) , or any subgroup thereof.
  • q is 1, 2, 3, 4, 5 or 6, or any subgroup thereof. In some embodiments, q is 2.
  • ql is 0, 1, 2 or 3, or any subgroup thereof.
  • q2 is 0, 1, 2 or 3, or any subgroup thereof.
  • R 2 is OR 3 ; and R 3 is Ci -6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein each of the Ci -6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted by 1 , 2, 3, 4 or 5 R 4 .
  • R 2 is OR 3 ; and R 3 is C 1-6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein each of the C 1-S alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, C 1-4 alkyl, C 1-4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, aryloxy, cycloalkyloxy, heteroaryloxy and heterocycloalkyloxy.
  • L is (CR 5 R 6 ) q ; and R 5 and R 6 are each, independently, H, halo, C 1-4 alkyl, C 1-4 haloalkyl CN, NO 2 , OH, C 1-4 alkoxy.
  • Q is aryl or heteroaryl, each substituted by 1 Cy 1 and optionally substituted by 1, 2, 3, or 4 A 1 ; and Cy 1 is aryl or heteroaryl, each optionally substituted with 1, 2, 3, 4 or 5 A 2 .
  • Q is aryl substituted by 1 Cy 1 and optionally substituted by 1, 2, 3, or 4 A 1 ; and Cy 1 is aryl or heteroaryl, each optionally substituted with 1, 2, 3, 4 or 5 A 2 .
  • Q is phenyl substituted by 1 Cy 1 and optionally substituted by I 5 2, 3, or 4 A 1 ; and Cy 1 is aryl or heteroaryl, each optionally substituted with 1, 2, 3, 4 or 5 A 2 .
  • Q is phenyl substituted by 1 Cy 1 at a meta-position and optionally substituted by 1, 2, 3, or 4 A 1 ; and Cy 1 is aryl or heteroaryl, each optionally substituted with 1, 2, 3, 4 or 5 A 2 .
  • R 1 is H, Ci -6 alkyl or C 1-6 haloalkyl
  • R 2 is chloro or OR 3
  • R 3 is C 1-6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein each of the C 1-6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, C 1-4 alkyl, C 1-4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, aryloxy, cycloalkyloxy, heteroaryloxy and heterocycloalkyloxy;
  • L is (CR 5 R 6 ) q ;
  • R 5 and R 6 are each, independently, H, halo, C 1-4 alkyl, C
  • Q is phenyl substituted by 1 Cy 1 and optionally substituted by 1, 2, 3, or 4 A 1 ; and Cy 1 is aryl or heteroaryl, each optionally substituted with 1, 2, 3, 4 or 5 A 2 .
  • t is 0 or 1
  • the other variables are defined as above.
  • q is 2 and Cy 1 is aryl or heteroaryl, each optionally substituted with 1, 2, 3, 4 or 5 A 2 , or any subgroup thereof.
  • R 1 is H, Ci -6 alkyl or C 1-6 haloalkyl
  • R 2 is chloro or OR 3
  • R 3 is Cj-6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, or any subgroup thereof, wherein each of the C 1-6 alkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, C 1-4 alkyl, C 1-4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyL CN, aryloxy, cycloalkyloxy, heteroaryloxy and heterocycloalkyloxy, or any subgroup thereof.
  • Compounds of the invention also include:
  • Compounds of the present invention also include pharmaceutically acceptable salts, tautomers and in vzvo-hydrolysable precursors of the compounds of any of the formulas described herein.
  • Compounds of the invention further include hydrates and solvates.
  • the present invention provides compounds of any of the formulas described herein, or pharmaceutically acceptable salts, tautomers or in vzvo-hydrolysable precursors thereof, for use as medicaments.
  • the present invention provides compounds described herein for use as as medicaments for treating or preventing an A ⁇ -related pathology.
  • the A ⁇ -related pathology is Downs syndrome, a ⁇ -amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
  • MCI mimild cognitive impairment
  • the present invention provides compounds of any of the formulas described herein, or pharmaceutically acceptable salts, tautomers or in vzvo-hydrolysable precursors thereof, in the manufacture of a medicament for the treatment or prophylaxis of A ⁇ -related pathologies.
  • the A ⁇ -related pathologies include such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
  • MCI mimild cognitive impairment
  • the present invention provides a method of inhibiting activity of BACE comprising contacting the BACE with a compound of the present invention.
  • BACE is thought to represent the major ⁇ -secretase activity, and is considered to be the rate-limiting step in the production of amyloid- ⁇ -protein (A ⁇ ).
  • a ⁇ amyloid- ⁇ -protein
  • BACE is an important candidate for the development of drugs as a treatment and/or prophylaxis of A ⁇ -related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
  • a ⁇ -related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated
  • the present invention provides a method for the treatment of A ⁇ -related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration, comprising administering to a mammal (including human) a therapeutically effective amount of a compound of any of the formulas described herein, or a pharmaceutically acceptable salt, tautomer or in vzv ⁇ -hydrolysable precursor thereof.
  • a ⁇ -related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral am
  • the present invention provides a method for the prophylaxis of A ⁇ -related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration comprising adm ⁇ iistering to a mammal (including human) a therapeutically effective amount of a compound of any of the formulas described herein or a pharmaceutically acceptable salt, tautomer or in v/v ⁇ -hydrolysable precursors.
  • a ⁇ -related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy,
  • the present invention provides a method of treating or preventing A ⁇ -related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration by administering to a mammal (including human) a compound of any of the formulas described herein or a pharmaceutically acceptable salt, tautomer or in vzvo-hydrolysable precursors and a cognitive and/or memory enhancing agent.
  • a ⁇ -related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral
  • the present invention provides a method of treating or preventing A ⁇ -related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated witii diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration by administering to a mammal (including human) a compound of any of the formulas described herein or a pharmaceutically acceptable salt, tautomer or in v/vo-hydrolysable precursors thereof wherein constituent members are provided herein, and a choline esterase inhibitor or anti-inflammatory agent.
  • a ⁇ -related pathologies such as Downs syndrome and ⁇
  • the present invention provides a method of treating or preventing A ⁇ -related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration, or any other disease, disorder, or condition described herein, by administering to a mammal (including human) a compound of the present invention, and an atypical antipsychotic agent.
  • a ⁇ -related pathologies such as Downs syndrome and ⁇ -amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage,
  • Atypical antipsychotic agents includes, but not limited to, Olanzapine (marketed as Zyprexa), Aripiprazole (marketed as Ability), Risperidone (marketed as Risperdal), Quetiapine (marketed as Seroquel), Clozapine (marketed as Clozaril), Ziprasidone (marketed as Geodon) and Olanzapine/Fluoxetine (marketed as Symbyax).
  • the mammal or human being treated with a compound of the present invention has been diagnosed with a particular disease or disorder, such as those described herein. In these cases, the mammal or human being treated is in need of such treatment. Diagnosis, however, need not be previously performed.
  • the anti-dementia treatment defined herein may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional chemotherapy.
  • chemotherapy may include one or more of the following categories of agents: acetyl cholinesterase inhibitors, anti-inflammatory agents, cognitive and/or memory enhancing agents or atypical antipsychotic agents.
  • Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment.
  • Such combination products employ the compounds of this invention.
  • Cognitive enhancing agents memory enhancing agents and choline esterase inhibitors includes, but not limited to, onepezil (Aricept), galantamine (Reminyl or Razadyne), rivastigmine (Exelon), tacrine (Cognex) and memantine (Namenda, Axura or Ebixa)
  • Atypical antipsychotic agents includes, but not limited to, olanzapine (marketed as Zyprexa), aripiprazole (marketed as Abilify), risperidone (marketed as Risperdal), quetiapine (marketed as Seroquel), clozapine (marketed as Clozaril), ziprasidone (marketed as Geodon) and olanzapine/fluoxetine (marketed as Symbyax).
  • the present invention also includes pharmaceutical compositions which contain, as the active ingredient, one or more of the compounds of the invention herein together with at least one pharmaceutically acceptable carrier, diluent or excipent.
  • compounds of the present invention When used for pharmaceutical compositions, medicaments, manufacture of a medicament, inhibiting activity of BACE, or treating or preventing A ⁇ -related pathologies, compounds of the present invention include the compounds of any of the formulas described herein, and pharmaceutically acceptable salts, tautomers and in vzv ⁇ -hydrolysable precursors thereof. Compounds of the present invention further include hydrates and solvates.
  • substitution means that substitution is optional and therefore it is possible for the designated atom or moiety to be unsubstituted.
  • substitution means that any number of hydrogens on the designated atom or moiety is replaced with a selection from the indicated group, provided that the normal valency of the designated atom or moiety is not exceeded, and that the substitution results in a stable compound.
  • a methyl group i.e., CH3
  • 3 hydrogens on the carbon atom can be replaced.
  • substituents include, but are not limited to: halogen, CN, NH 2 , OH, SO, SO 2 , COOH, OCi -6 alkyl, CH 2 OH, SO 2 H 5 C 1-6 alkyl, OCi -6 alkyl, C(-O)C 1-6 alkyl, C(O)0C 1-6 alkyl, SO 2 C 1-6 alkyl, SO 2 NHC 1-6 alkyl, SO 2 N(C 1-6 alkyl) 2 , NH(C 1-6 alkyl), N(C 1 .
  • a variety of compounds in the present invention may exist in particular geometric or stereoisomers forms.
  • the present invention takes into account all such compounds, including cis- and trans isomers, R- and S- enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as being covered within the scope of this invention.
  • Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group.
  • AU such isomers, as well as mixtures thereof, are intended to be included in this invention.
  • the compounds herein described may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms.
  • optically active forms such as by resolution of racemic forms or by synthesis from optically active starting materials.
  • separation of the racemic material can be achieved by methods known in the art.
  • Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. AU chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated.
  • alkyl As used herein, "alkyl”, “alkylenyl” or “alkylene” used alone or as a suffix or prefix, is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having from 1 to 12 carbon atoms or if a specified number of carbon atoms is provided then that specific number would be intended.
  • C 1-6 alkyl denotes alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms.
  • alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, pentyl, and hexyl.
  • alkenyl refers to an alkyl group having one or more double carbon-carbon bonds.
  • Example alkenyl groups include ethenyl, propenyl, cyclohexenyl, and the like.
  • alkenylenyl refers to a divalent linking alkenyl group.
  • alkynyl refers to an alkyl group having one or more triple carbon-carbon bonds.
  • Example alkynyl groups include ethynyl, propynyl, and the like.
  • alkynylenyl refers to a divalent linking alkynyl group.
  • aromatic refers to hydrocarbyl groups having one or more polyunsaturated carbon rings having aromatic characters, (e.g., 4n + 2 delocalized electrons) and comprising up to about 14 carbon atoms.
  • aryl refers to an aromatic ring structure made up of from 5 to 14 carbon atoms. Ring structures containing 5, 6, 7 and 8 carbon atoms would be single-ring aromatic groups, for example, phenyl. Ring structures containing 8, 9, 10, 11, 12, 13, or 14 would be a polycyclic moiety in which at least one carbon is common to any two adjoining rings therein (for example, the rings are "fused rings"), for example naphthyl.
  • the aromatic ring can be substituted at one or more ring positions with such substituents as described above.
  • aryl also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are "fused rings") wherein at least one of the rings is aromatic, for example, the other cyclic rings can be cycloalkyls, cycloalkenyls or cycloalkynyls.
  • ortho, meta and para apply to 1,2-, 1,3- and 1,4-disubstituted benzenes, respectively.
  • the names 1,2-dimethylbenzene and ortho-dimethylbenzene are synonymous.
  • cycloalkyl refers to non-aromatic cyclic hydrocarbons including cyclized alkyl, alkenyl, and alkynyl groups, having the specified number of carbon atoms. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused or bridged rings) groups.
  • Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, adamantyl, and the like.
  • cycloalkyl moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo derivatives of cyclopentane (i.e., indanyl), cyclopentene, cyclohexane, and the like.
  • cycloalkyl further includes saturated ring groups, having the specified number of carbon atoms. These may include fused or bridged polycyclic systems.
  • Preferred cycloalkyls have from 3 to 10 carbon atoms in their ring structure, and more preferably have 3, 4, 5, and 6 carbons in the ring structure.
  • C 3-6 cycloalkyl denotes such groups as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. .
  • cycloalkenyl refers to ring-containing hydrocarbyl groups having at least one carbon-carbon double bond in the ring, and having from 3 to 12 carbons atoms.
  • halo or “halogen” refers to ftuoro, chloro, bromo, and iodo.
  • Counterion is used to represent a small, negatively or positively charged species such as chloride (Cl “ ), bromide (Br ' ), hydroxide (OH “ ), acetate (CH 3 COO “ ) , sulfate (SO4 2” ), tosylate (CH 3 -phenyl-SO 3 " ), benezensulfonate (phenyl-SO 3 " ), sodium ion (Na + ), potassium (K + ), ammonium (NH 4 + ), and the like.
  • heterocyclyl or “heterocyclic” or “heterocycle” refers to a ring-containing monovalent and divalent structures having one or more heteroatoms, independently selected from N, O and S, as part of the ring structure and comprising from 3 to 20 atoms in the rings, more preferably 3- to 7- membered rings.
  • the number of ring-forming atoms in heterocyclyl are given in ranges herein.
  • Cs -10 heterocyclyl refers to a ring structure comprising from 5 to 10 ring-forming atoms wherein at least one of the ring-forming atoms is N, O or S.
  • Heterocyclic groups may be saturated or partially saturated or unsaturated, containing one or more double bonds, and heterocyclic groups may contain more than one ring as in the case of polycyclic systems.
  • the heterocyclic rings described herein may be substituted on carbon or on a heteroatom atom if the resulting compound is stable. If specifically noted, nitrogen in the heterocyclyl may optionally be quaternized. It is understood that when the total number of S and O atoms in the heterocyclyl exceeds 1, then these heteroatoms are not adjacent to one another.
  • heterocyclyls include, but are not limited to, lH-indazole, 2-pyrrolidonyl, 2H, 6H- 1, 5,2-dithiazinyl, 2H-pyirolyl 5 3H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H-quinolizinyl, 6H- 1, 2,5-thiadiazinyl, acridinyl, azabicyclo, azetidine, azepane, aziridine, azocinyl, benzimidazolyl, benzodioxol, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4aH-carbazolyl,
  • heteroaryl refers to an aromatic heterocycle having at least one heteroatom ring member such as sulfur, oxygen, or nitrogen.
  • Heteroaryl groups include monocyclic and polycyclic (e.g., having 2, 3 or 4 fused rings) systems. Examples of heteroaryl groups include without limitation, pyridyl (i.e., pyridinyl), pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl (i.e.
  • the heteroaryl group has from 1 to about 20 carbon atoms, and in further embodiments from about 3 to about 20 carbon atoms.
  • the heteroaryl group contains 3 to about 14, 4 to about 14, 3 to about 7, or 5 to 6 ring-forming atoms. In some embodiments, the heteroaryl group has 1 to about 4, 1 to about 3, or 1 to 2 heteroatoms. In some embodiments, the heteroaryl group has 1 heteroatom.
  • alkoxy or "alkyloxy” represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge.
  • alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, t-butoxy, n-pentoxy, isopentoxy, cyclopropylmethoxy, allyloxy and propargyloxy.
  • alkylmio or “thioalkoxy” represent an alkyl group as defined above with the indicated number of carbon atoms attached through a sulphur bridge.
  • carbonyl is art recognized and includes such moieties as can be represented by the general formula:
  • X is a bond or represents an oxygen or sulfur
  • R represents a hydrogen, an alkyl, an alkenyl, -(CH 2 ) m -R' ' or a pharmaceutically acceptable salt
  • R' represents a hydrogen, an alkyl, an alkenyl or -(CH 2 ) m -R", where m is an integer less than or equal to ten
  • R' ' is alkyl, cycloalkyl, alkenyl, aryl, or heteroaryl.
  • sulfonyl refers to a moiety that can be represented by the general formula:
  • R is represented by but not limited to hydrogen, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, aralkyl, or heteroaralkyl.
  • arylalkyl and “arylakyloxy” are meant to refer to a type of structure as exemplified by the two depicted variants, respectively:
  • Arylalkyl and “arylakyloxy” are meant to refer to a type of structure as exemplified by the two depicted variants, respectively:
  • protecting group means temporary substituents which protect a potentially reactive functional group from undesired chemical transformations.
  • protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones respectively.
  • the field of protecting group chemistry has been reviewed (Greene, T.W.; Wuts, P.G.M. Protective Groups in Organic Synthesis, 3 rd ed; Wiley: New York, 1999).
  • pharmaceutically acceptable is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof (i.e., also include counterions).
  • pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, phosphoric, and the like; and the salts prepared from organic acids such as lactic, maleic, citric, benzoic, methanesulfonic, and the like.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound that contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile can be used.
  • in vivo hydrolysable precursors means an in vivo hydroysable (or cleavable) ester of a compound of any of the formulas described herein that contains a carboxy or a hydroxy group.
  • amino acid esters Ci -6 alkoxymethyl esters like methoxymethyl; Ci.6alkanoyloxyrnetb.yl esters like pivaloyloxymethyl; C 3- gcycloalkoxycarbonyloxy C 1-6 alkyl esters like 1-cyclohexylcarbonyloxy ethyl, acetoxymethoxy, or phosphoramidic cyclic esters,
  • tautomer means other structural isomers that exist in equilibrium resulting from the migration of a hydrogen atom. For example, keto-enol tautomerism where the resulting compound has the porperties of both a ketone and an unsturated alchol.
  • stable compound and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • the present invention further includes isotopically-labeled compounds of the invention.
  • An “isotopically” or “radio-labeled” compound is a compound of the invention where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring).
  • Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to 2 H (also written as D for deuterium), 3 H (also written as T for tritium), 11 C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 0, 18 0, 18 F, 35 S, 36 Cl, 82 Br, 75 Br, 76 Br, 77 Br, 123 1, 124 1, 125 I and 131 I.
  • the radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for in vitro receptor labeling and competition assays, compounds that incorporate 3 H 3 14 C, 82 Br, 125 1 , 131 1, 35 S or will generally be most useful. For radio-imaging applications 11 C, 18 F, 125 1, 123 1, 124 1, 131 1, 75 Br, 76 Br or 77 Br will generally be most useful.
  • a "radio-labeled compound” is a compound that has incorporated at least one radionuclide.
  • the radionuclide is selected from the group consisting of 3 H, 14 C, 125 1 , 35 S and 82 Br.
  • the antidementia treatment defined herein may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional chemotherapy.
  • Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment.
  • Such combination products employ the compounds of this invention.
  • Compounds of the present invention may be administered orally, parenteral, buccal, vaginal, rectal, inhalation, insufflation, sublingually, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracially, intravenously, epidurally, intrathecally, intracerebroventricularly and by injection into the joints.
  • the dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, when determining the individual regimen and dosage level as the most appropriate for a particular patient.
  • An effective amount of a compound of the present invention for use in therapy of dementia is an amount sufficient to symptomatically relieve in a warm-blooded animal, particularly a human the symptoms of dementia, to slow the progression of dementia, or to reduce in patients with symptoms of dementia the risk of getting worse.
  • inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.
  • a solid carrier can be one or more substances, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
  • the carrier is a finely divided solid, which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • a low-melting wax such as a mixture of fatty acid s glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify.
  • Suitable carriers include magnesium carbonate, magnesium stearate, talc, lactose, sugar, o pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.
  • Some of the compounds of the present invention are capable of forming salts with various inorganic and organic acids and bases and such salts are also within the scope of this s invention.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, phosphoric, and the like; and the salts prepared from organic acids such as lactic, maleic, citric, benzoic, methanesulfonic, trifluoroacetate and the like.
  • the present invention provides a compound of any of the formulas described herein or a pharmaceutically acceptable salt thereof for the therapeutic treatment (including prophylactic treatment) of mammals including humans, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
  • the pharmaceutical composition of this invention may also contain, or be co-administered (simultaneously or sequentially) with, one or more pharmacological agents of value in treating one or more disease conditions referred to herein.
  • composition is intended to include the formulation of the active component or a pharmaceutically acceptable salt with a pharmaceutically acceptable carrier.
  • this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols or nebulisers for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions.
  • Liquid form compositions include solutions, suspensions, and emulsions.
  • Sterile water or water-propylene glycol solutions of the active compounds may be mentioned as an example of liquid preparations suitable for parenteral administration.
  • Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution.
  • Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired.
  • Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.
  • the pharmaceutical compositions can be in unit dosage form.
  • the composition is divided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparations, for example, packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms.
  • compositions may be formulated for any suitable route and means of administration.
  • Pharmaceutically acceptable carriers or diluents include those used in formulations suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural) administration.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy.
  • conventional non-toxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, cellulose, cellulose derivatives, starch, magnesium stearate, sodium saccharin, talcum, glucose, sucrose, magnesium carbonate, and the like may be used.
  • Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc, an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension.
  • the pharmaceutical composition to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc.
  • auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc.
  • the compounds of the invention may be derivatised in various ways.
  • derivatives of the compounds includes salts (e.g. pharmaceutically acceptable salts), any complexes (e.g. inclusion complexes or clathrates with compounds such as cyclodextrins, or coordination complexes with metal ions such as Mn 2+ and Zn 2+ ), esters such as in vivo hydrolysable esters, free acids or bases, polymorphic forms of the compounds, solvates (e.g. hydrates), prodrugs or lipids, coupling partners and protecting groups.
  • prodrugs is meant for example any compound that is converted in vivo into a biologically active compound.
  • Salts of the compounds of the invention are preferably physiologically well tolerated and 5 non toxic. Many examples of salts are known to those skilled in the art. All such salts are within the scope of this invention, and references to compounds include the salt forms of the compounds.
  • Compounds having acidic groups can form I 0 salts with alkaline or alkaline earth metals such as Na, K, Mg and Ca, and with organic amines such as triethylamine and Tris (2-hydroxyethyl)amine. Salts can be formed between compounds with basic groups, e.g. amines, with inorganic acids such as hydrochloric acid, phosphoric acid or sulfuric acid, or organic acids such as acetic acid, citric acid, benzoic acid, fumaric acid, or tartaric acid.
  • Compounds having both acidic and is basic groups can form internal salts.
  • Acid addition salts may be formed with a wide variety of acids, both inorganic and organic.
  • Examples of acid addition salts include salts formed with hydrochloric, hydriodic, phosphoric, nitric, sulphuric, citric, lactic, succinic, maleic, malic, isethionic, fumaric, 2o benzenesulphonic, toluenesulphonic, methanesulphonic, ethanesulphonic, naphthalenesulphonic, valeric, acetic, propanoic, butanoic, malonic, glucuronic and lactobionic acids.
  • a salt may be formed with a suitable cation.
  • suitable inorganic cations include, but are not limited to, alkali metal ions such as Na + and K + , alkaline earth cations such as Ca 2+ and Mg 2+ , and other cations such as Al 3+ .
  • suitable organic cations include, but are not limited to, ammonium ion (i.e., NH 4 + ) and substituted ammonium ions (e.g., NH 3 R + , NH 2 R 2 + , NHR 3 + , NR 4 + ).
  • Examples of some 3 o suitable substituted ammonium ions are those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine.
  • An example of a common quaternary ammonium ion is N(CH 3 ) 4 + .
  • the compounds may contain an amine function, these may form quaternary ammonium salts, for example by reaction with an alkylating agent according to methods well known to the skilled person. Such quaternary ammonium compounds are within the scope of the invention.
  • Compounds containing an amine function may also form N-oxides.
  • a reference herein to a compound that contains an amine function also includes the N-oxide.
  • N-oxides are the N-oxides of a tertiary amine or a nitrogen atom of a nitrogen-containing heterocycle.
  • N-Oxides can be formed by treatment of the corresponding amine with an oxidizing agent such as hydrogen peroxide or a per-acid (e.g. a peroxycarboxylic acid), see for example Advanced Organic Chemistry, by Jerry March, 4 th Edition, Wiley Interscience, pages. More particularly, N-oxides can be made by the procedure of L. W. Deady (Syn. Comm. 1977, 7, 509-514) in which the amine compound is reacted with m-chloroperoxybenzoic acid (MCPBA), for example, in an inert solvent such as dichloromethane.
  • MCPBA m-chloroperoxybenzoic acid
  • Esters can be formed between hydroxyl or carboxylic acid groups present in the compound and an appropriate carboxylic acid or alcohol reaction partner, using techniques well known in the art.
  • R is an acyloxy substituent, for example, a C 1-7 alkyl group, a C 3-20 heterocyclyl group, or a C 5-20 aryl group, preferably a C 1-7 alkyl group.
  • prodrugs which are prodrugs of the compounds are convertible in vivo or in vitro into one of the parent compounds. Typically, at least one of the biological activities of compound will be reduced in the prodrug form of the compound, and can be activated by conversion of the prodrug to release the compound or a metabolite of it.
  • Some prodrugs are esters of the active compound (e.g., a physiologically acceptable nietabolically labile ester).
  • esters may be formed by esterification, for example, of any of the carboxylic acid groups (-C( ⁇ O)OH) in the parent compound, with, where appropriate, prior protection of any other reactive groups present in the parent compound, followed by deprotection if required.
  • some prodrugs are activated enzymatically to yield the active compound, or a compound which, upon further chemical reaction, yields the active compound (for example, as in ADEPT 3 GDEPT, LIDEPT 5 etc.).
  • the prodrug may be a sugar derivative or other glycoside conjugate, or may be an amino acid ester derivative.
  • Other derivatives include coupling partners of the compounds in which the compounds is linked to a coupling partner, e.g. by being chemically coupled to the compound or physically associated with it. Examples of coupling partners include a label or reporter molecule, a supporting substrate, a carrier or transport molecule, an effector, a drug, an antibody or an inhibitor. Coupling partners can be covalently linked to compounds of the invention via an appropriate functional group on the compound such as a hydroxyl group, a carboxyl group or an amino group. Other derivatives include formulating the compounds with liposomes.
  • the quantity of the compound to be administered will vary for the patient being treated and will vary from about 100 ng/kg of body weight to 100 mg/kg of body weight per day and preferably will be from 10 pg/kg to 10 mg/kg per day.
  • dosages can be readily ascertained by those skilled in the art from this disclosure and the knowledge in the art.
  • the skilled artisan can readily determine the amount of compound and optional additives, vehicles, and/or carrier in compositions and to be administered in methods of the invention.
  • Beta secretase including BACE
  • Inhibitors of beta secretase have been shown to be useful in blocking formation or aggregation of A ⁇ peptide and therefore have a beneficial effects in treatment of Alzheimer's Disease and other neurodegenerative diseases associated with elevated levels and/or deposition of A ⁇ peptide. Therefore it is believed that the compounds of the present invention may be used for the treatment of Alzheimer disease and disease associated with dementia.
  • compounds of the present invention and their salts are expected to be active against age-related diseases such as Alzheimer, as well as other A ⁇ related pathologies such as Down's syndrome and b-amyloid angiopathy. It is expected that the compounds of the present invention would most likely be used in combination with a broad range of cognition deficit enhancement agents but could also be used as a single agent.
  • the compounds of the present invention have been identified in one or both assays described below as having an IC5 0 value of 100 micromolar or less.
  • Enzyme is diluted 1:30 in 40 mM MES pH 5.0.
  • Stock substrate is diluted to 12 ⁇ M in 40 mM MES pH 5.0.
  • PALMEB solution is added to the substrate solution (1:100 dilution).
  • DMSO stock solutions of compounds or DMSO alone are diluted to the desired concentration in 4OmM MES pH 5.0.
  • the assay is done in a 96 well PCR plate from Nunc. Compound in DMSO (3 ⁇ L) is added to the plate then enzyme is added (27 ⁇ L) and pre-incubated with compound for 5 minutes. Then the reaction is started with substrate (30 ⁇ L).
  • the final dilution of enzyme is 1 :60; the final concentration of substrate is 6 ⁇ M (Km is 150 ⁇ M).
  • reaction After a 20 minute reaction at room temperature, the reaction is stopped by removing 10 ⁇ l of the reaction mix and diluting it 1:25 in 0.20M Tris pH 8.0. The compounds are added to the plate by hand then all the rest of the liquid handling is done on the CyBi-well instrument.
  • AU antibodies and the streptavidin coated beads are diluted into PBS containing 0.5% BSA and 0.5% Tween20.
  • the product is quantified by adding 50 ⁇ L of a 1:5000 dilution of the neoepitope antibody to 50 ⁇ L of the 1:25 dilution of the reaction mix. Then, 100 ⁇ L of PBS (0.5% BSA, 0.5% Tween20) containing 0.2 mg/ml IGEN beads and a 1:5000 dilution of ruthinylated goat anti-rabbit (Ru-Gar) antibody is added.
  • the final dilution of neoepitope antibody is 1 :20,000
  • the final dilution of Ru-GAR is 1 : 10,000
  • the final concentration of beads is 0.1 mg/ml.
  • the mixture is read on the IGEN instrument with the CindyAB40 program after a 2-hour incubation at room temperature. Addition of DMSO alone is used to define the 100% activity. 20 ⁇ M control inhibitor is used to define 0% of control activity and 100 nM inhibitor defines 50% control of control activity in single-poke assays. Control inhibitor is also used in dose response assays with an IC50 of 100 nM.
  • Enzyme is diluted 1 :30 in 4OmM MES pH 5.0.
  • Stock substrate is diluted to 30 ⁇ M in 40 mM MES pH 5.0.
  • PALMEB solution is added to the substrate solution (1:100 dilution).
  • Enzyme and substrate stock solutions are kept on ice until the placed in the stock plates.
  • the Platemate-plus instrument is used to do all liquid handling.
  • En2yme (9 ⁇ L) is added to the plate then 1 ⁇ L of compound in DMSO is added and pre-incubated for 5 minutes.
  • the dilutions are done in neat DMSO and the DMSO stocks are added as described above.
  • Substrate (10 ⁇ L) is added and the reaction proceeds in the dark for 1 hour at room temperature.
  • the assay is done in a Corning 384 well round bottom, low volume, non-binding surface (Corning #3676).
  • the final dilution of enzyme is 1 :60; the final concentration of substrate is 15 ⁇ M (Km of 25 ⁇ M).
  • the fluorescence of the product is measured on a Victor II plate reader with an excitation wavelength of 360nm and an emission wavelength of 485 nm using the protocol labeled Edans peptide.
  • the DMSO control defines the 100% activity level and 0% activity is defined by using 50 ⁇ M of the control inhibitor, which completely blocks enzyme function.
  • the control inhibitor is also used in dose response assays and has an IC50 of 95 nM.
  • HEK-Fc33-1 The cDNA encoding full length BACE was fused in frame with a three amino acid linker . (Ala-Val-Thr) to the Fc portion of the human IgGl starting at amino acid 104.
  • the BACE-Fc construct was then cloned into a GFP/pGEN-IRES-neoK vector (a proprietary vector of AstraZeneca) for protein expression in mammalian cells.
  • the expression vector was stably transfected into HEK-293 cells using a calcium phosphate method. Colonies were selected with 250 ⁇ g/mL of G-418. Limited dilution cloning was performed to generate homogeneous cell lines. Clones were characterized by levels of APP expression and A ⁇ secreted in the conditioned media using an ELISA assay developed in-house. A ⁇ secretion of BACE/Fc clone Fc33-1 was moderate.
  • HEK293 cells stably expressing human BACE (HEK-Fc33) were grown at 37 0 C in DMEM containing 10% heat-inhibited FBS, 0.5 mg/mL antibiotic-antimycotic solution, and 0.05 mg/mL of the selection antibiotic G-418.
  • a ⁇ 40 Release Assay Cells were harvested when between 80 to 90% confluent. 100 ⁇ L of cells at a cell density of 1.5 million/mL were added to a white 96- well cell culture plate with clear flat bottom (Costar 3610), or a clear, flat bottom 96-well cell culture plate (Costar 3595), containing 100 ⁇ L of inhibitor in cell culture medium with DMSO at a final concentration of 1%. After the plate was incubated at 37°C for 24 h, 100 ⁇ L cell medium was transferred to a round bottom 96-well plate (Costar 3365) to quantify A ⁇ 40 levels. The cell culture plates were saved for ATP assay as described in ATP assay below.
  • the plate was shaken at 22°C on a plate shaker for 1 h, and then the plates were then measured for ECL counts in an IGEN M8 Analyzer.
  • a ⁇ standard curves were obtained with 2-fold serial dilution of an A ⁇ stock solution of known concentration in the same cell culture medium used in cell-based assays.
  • the plates which still contained cells, were saved for cytotoxicity assays by using the assay kit (ViaLightTM Plus) from Cambrex BioScience that measures total cellular ATP. Briefly, to each well of the plates, 50 ⁇ L cell lysis reagent was added. The plates were incubated at room temperature for 10 min. Two min following addition of 100 ⁇ L reconstituted ViaLightTM Plus reagent for ATP measurement, the luminescence of each well was measured in an LJL plate reader or Wallac Topcount.
  • the assay kit ViaLightTM Plus
  • BACE was assayed on a Biacore3000 instrument by attaching either a peptidic transition state isostere (TSI) or a scrambled version of the peptidic TSI to the surface of a Biacore CM5 sensor chip.
  • TSI transition state isostere
  • the surface of a CM5 sensor chip has 4 distinct channels that can be used to couple the peptides.
  • the scrambled peptide KFES-statine-ETIAEVENV was coupled to channel 1 and the TSI inhibitor KTEEISEVN-statine-VAEF was couple to channel 2 of the same chip.
  • the two peptides were dissolved at 0.2 mg/ml in 20 mM Na Acetate pH 4.5, and then the solutions were centrifuged at 14K rpm to remove any particulates.
  • Carboxyl groups on the dextran layer were activated by injecting a one to one mixture of O.5M N-ethyl-N' (3-dimethylaminopropyl)-carbodiimide (EDC) and 0.5M N-hydroxysuccinimide (NHS) at 5 ⁇ L/minute for 7 minutes.
  • EDC O.5M N-ethyl-N' (3-dimethylaminopropyl)-carbodiimide
  • NHS N-hydroxysuccinimide
  • the BACE Biacore assay was done by diluting BACE to 0.5 ⁇ M in Na Acetate buffer at pH 4.5 (running buffer minus DMSO). The diluted BACE was mixed with DMSO or compound diluted in DMSO at a final concentration of 5% DMSO. The BACE/inhibitor mixture was incubated for 1 hour at 4°C then injected over channel 1 and 2 of the CM5 Biacore chip at a rate of 20 ⁇ L/minute. As BACE bound to the chip the signal was measured in response units (RU). BACE binding to the TSI inhibitor on channel 2 gave a certain signal. The presence of a BACE inhibitor reduced the signal by binding to BACE and inhibiting the interaction with the peptidic TSI on the chip. Any binding to channel 1 was non-specific and was subtracted from the channel 2 responses. The DMSO control was defined as 100% and the effect of the compound was reported as percent inhibition of the DMSO control.
  • the hERG-expressing Chinese hamster ovary Kl (CHO) cells described by (Persson, Carlsson, Duker, & Jacobson, 2005) were grown to semi-confluence at 37 0 C in a humidified environment (5% CO 2 ) in F- 12 Ham medium containing L-glutamine, 10% foetal calf serum (FCS) and 0.6 mg/ml hygromycin (all Sigma- Aldrich). Prior to use, the monolayer was washed using a pre-warmed (37 0 C) 3 ml aliquot of Versene 1:5,000 (Invitrogen).
  • PatchPlate in which a recording is attempted in each well by using suction to position and hold a cell on a small hole separating two isolated fluid chambers. Once sealing has taken place, the solution on the underside of the PatchPlateTM is changed to one containing amphotericin B. This permeablises the patch of cell membrane covering the hole in each well and, in effect, allows a perforated, whole-cell patch clamp recording to be made.
  • a ⁇ -test IonWorksTM HT from Essen Instrument was used. There is no capability to warm solutions in this device hence it was operated at room temperature ( ⁇ 21°C), as follows.
  • the reservoir in the "Buffer” position was loaded with 4 ml of PBS and that in the "Cells” position with the CHO-hERG cell suspension described above.
  • a 96-well plate (V-bottom, Greiner Bio-one) containing the compounds to be tested (at 3-fold above their final test concentration) was placed in the "Plate 1" position and a PatchPlateTM was clamped into the PatchPlateTM station.
  • Each compound plate was laid-out in 12 columns to enable ten, 8- point concentration-effect curves to be constructed; the remaining two columns on the plate were taken up with vehicle (final concentration 0.33% DMSO), to define the assay baseline, and a supra-maximal blocking concentration of cisapride (final concentration 10 ⁇ M) to define the 100% inhibition level.
  • the fluidics-head (F-Head) of IonWorksTM HT then added 3.5 ⁇ l of PBS to each well of the PatchPlateTM and its underside was perfused with "internal" solution that had the following composition (in mM): K-Gluconate 100, KCl 40, MgCl 2 3.2, EGTA 3 and HEPES 5 (all Sigma-Aldrich; pH 7.25-7.30 using 10 M KOH).
  • the electronics-head (E-head) then moved round the PatchPlateTM performing a hole test (i.e. applying a voltage pulse to determine whether the hole in each well was open).
  • the F-head then dispensed 3.5 ⁇ l of the cell suspension described above into each well of the PatchPlateTM and the cells were given 200 seconds to reach and seal to the hole in each well. Following this, the E-head moved round the PatchPlateTM to determine the seal resistance obtained in each well.
  • the solution on the underside of the PatchPlateTM was changed to "access" solution that had the following composition (in mM): KCl 140, EGTA 1, MgCl 2 1 and HEPES 20 (pH 7.25-7.30 using 10 M KOH) plus 100 ⁇ g/ml of amphotericin B (Sigma-Aldrich).
  • the E-head moved round the PatchPlateTM 48 wells at a time to obtain pre-compound hERG current measurements.
  • the F-head then added 3.5 ⁇ l of solution from each well of the compound plate to 4 wells on the PatchPlateTM (the final DMSO concentration was 0.33% in every well). This was achieved by moving from the most dilute to the most concentrated well of the compound plate to minimise the impact of any compound carry-over.
  • the E-head then moved around all 384- wells of the PatchPlateTM to obtain post-compound hERG current measurements. In this way, non-cumulative concentration-effect curves could be produced where, providing the acceptance criteria were achieved in a sufficient percentage of wells (see below), the effect of each concentration of test compound was based on recording from between 1 and 4 cells.
  • the pre- and post-compound hERG current was evoked by a single voltage pulse consisting of a 20 s period holding at -70 mV, a 160 ms step to -60 mV (to obtain an estimate of leak), a 100 ms step back to -70 mV, a 1 s step to + 40 mV, a 2 s step to -30 mV and finally a 500 ms step to -7OmV.
  • a single voltage pulse consisting of a 20 s period holding at -70 mV, a 160 ms step to -60 mV (to obtain an estimate of leak), a 100 ms step back to -70 mV, a 1 s step to + 40 mV, a 2 s step to -30 mV and finally a 500 ms step to -7OmV.
  • Currents were leak-subtracted based on the estimate of current evoked during the +1OmV step at the start of the
  • any voltage offsets in IonWorksTM HT were adjusted in one of two ways.
  • a depolarising voltage ramp was applied to CHO- KvI .5 cells and the voltage noted at which there was an inflection point in the current trace (i.e. the point at which channel activation was seen with a ramp protocol).
  • the voltage at which this occurred had previously been determined using the same voltage command in conventional electrophysiology and found to be -15 mV (data not shown); thus an offset potential could be entered into the IonWorksTM HT software using this value as a reference point.
  • any offset was adjusted by determining the hERG tail current reversal potential in IonWorksTM HT, comparing it with that found in conventional electrophysiology (-82 mV; see Fig. Ic) and then making the necessary offset adjustment in the IonWorksTM HT software.
  • the current signal was sampled at 2.5 kHz.
  • Pre- and post-scan hERG current magnitude was measured automatically from the leak subtracted traces by the IonWorksTM HT software by taking a 40 ms average of the current during the initial holding period at -70 mV (baseline current) and subtracting this from the peak of the tail current response.
  • the acceptance criteria for the currents evoked in each well were: pre-scan seal resistance >60 M ⁇ , pre-scan hERG tail current amplitude >150 pA; post-scan seal resistance >60 M ⁇ .
  • the degree of inhibition of the hERG current was assessed by dividing the post-scan hERG current by the respective pre-scan hERG current for each well.
  • the compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis.
  • the compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Such methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety by reference.
  • novel compounds of this invention may be prepared using the reactions and techniques described herein.
  • the reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected.
  • all proposed reaction conditions including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled in the art.
  • the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents, which are not compatible with the reaction conditions, will be readily apparent to one skilled in the art and alternate methods must then be used.

Abstract

L'invention concerne des nouveaux composés de formule structurelle (I) et leurs sels pharmaceutiquement acceptables, leurs compositions et leurs procédés d'utilisation. Les nouveaux composés de l'invention sont utilisés dans le traitement ou la prophylaxie de la déficience cognitive, de la maladie d'Alzheimer, de la neurodégénérescence et de la démence.
PCT/SE2006/001281 2005-11-15 2006-11-13 Nouveaux derives de 2-aminopyrimidine derivatives et leur utilisation WO2007058581A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/093,646 US20080255167A1 (en) 2005-11-15 2006-11-13 Novel 2-Aminopyrimidine or 2-Aminiopyridinone Derivatives and Their Use
EP06813004A EP1951681A4 (fr) 2005-11-15 2006-11-13 Nouveaux derives de 2-aminopyrimidine derivatives et leur utilisation
JP2008541108A JP2009515950A (ja) 2005-11-15 2006-11-13 新規な２−アミノピリミジン誘導体およびその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73743505P 2005-11-15 2005-11-15
US60/737,435 2005-11-15

Publications (1)

Publication Number Publication Date
WO2007058581A1 true WO2007058581A1 (fr) 2007-05-24

Family

ID=38048894

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2006/001281 WO2007058581A1 (fr) 2005-11-15 2006-11-13 Nouveaux derives de 2-aminopyrimidine derivatives et leur utilisation

Country Status (5)

Country Link
US (1) US20080255167A1 (fr)
EP (1) EP1951681A4 (fr)
JP (1) JP2009515950A (fr)
CN (1) CN101360722A (fr)
WO (1) WO2007058581A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855213B2 (en) 2006-06-22 2010-12-21 Astrazeneca Ab Compounds
US8030500B2 (en) 2008-11-14 2011-10-04 Astrazeneca Ab Substituted isoindoles for the treatment and/or prevention of Aβ- related pathologies
US8183252B2 (en) 2003-12-15 2012-05-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US8557826B2 (en) 2009-10-08 2013-10-15 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use
US8563543B2 (en) 2009-10-08 2013-10-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8569310B2 (en) 2009-10-08 2013-10-29 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use
US8729071B2 (en) 2009-10-08 2014-05-20 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9181236B2 (en) 2011-08-22 2015-11-10 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077277A1 (es) * 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018758A1 (fr) * 1998-09-25 2000-04-06 Mitsubishi Chemical Corporation Derives pyrimidone
WO2001062233A2 (fr) * 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Modulateurs de recepteurs de l'adenosine
WO2004016605A1 (fr) * 2002-08-19 2004-02-26 Fujisawa Pharmaceutical Co., Ltd. Derives de 2-aminopyrimidine utilises en tant qu'antagonistes des recepteurs a2a et a1 de l'adenosine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062282A1 (en) * 2004-10-15 2009-03-05 Astrazeneca Ab Substituted Amino-Pyrimidones and Uses Thereof
US20090221579A1 (en) * 2004-10-15 2009-09-03 Jeffrey Scott Albert Substituted Amino-Compounds and Uses Thereof
MX2007016185A (es) * 2005-06-14 2008-03-07 Schering Corp Inhibidores de aspartil proteasa heterociclicos macrociclicos.
US7759353B2 (en) * 2005-06-14 2010-07-20 Schering Corporation Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods of treatment
JP2009513670A (ja) * 2005-10-31 2009-04-02 シェーリング コーポレイション アスパルチルプロテアーゼインヒビター

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018758A1 (fr) * 1998-09-25 2000-04-06 Mitsubishi Chemical Corporation Derives pyrimidone
WO2001062233A2 (fr) * 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Modulateurs de recepteurs de l'adenosine
WO2004016605A1 (fr) * 2002-08-19 2004-02-26 Fujisawa Pharmaceutical Co., Ltd. Derives de 2-aminopyrimidine utilises en tant qu'antagonistes des recepteurs a2a et a1 de l'adenosine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1951681A4 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183252B2 (en) 2003-12-15 2012-05-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7855213B2 (en) 2006-06-22 2010-12-21 Astrazeneca Ab Compounds
US8691833B2 (en) 2007-02-23 2014-04-08 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
US8829036B2 (en) 2007-02-23 2014-09-09 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
US8691831B2 (en) 2007-02-23 2014-04-08 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
US8030500B2 (en) 2008-11-14 2011-10-04 Astrazeneca Ab Substituted isoindoles for the treatment and/or prevention of Aβ- related pathologies
US8729071B2 (en) 2009-10-08 2014-05-20 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use
US8569310B2 (en) 2009-10-08 2013-10-29 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use
US8563543B2 (en) 2009-10-08 2013-10-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8557826B2 (en) 2009-10-08 2013-10-15 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use
US8940748B2 (en) 2009-10-08 2015-01-27 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9029362B2 (en) 2009-10-08 2015-05-12 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as brace inhibitors, compositions, and their use
US9428475B2 (en) 2009-10-08 2016-08-30 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9475785B2 (en) 2009-10-08 2016-10-25 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use
US9687494B2 (en) 2009-10-08 2017-06-27 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9181236B2 (en) 2011-08-22 2015-11-10 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use

Also Published As

Publication number Publication date
EP1951681A1 (fr) 2008-08-06
EP1951681A4 (fr) 2011-06-15
JP2009515950A (ja) 2009-04-16
CN101360722A (zh) 2009-02-04
US20080255167A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
US20080255164A1 (en) Novel 2-Aminopyrimidinone Derivatives And Their Use
US20080318985A1 (en) Novel 2-Aminopyrimidinone Or 2-Aminopyridinone Derivatives and Their Use
US20080293709A1 (en) Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies
US20080255167A1 (en) Novel 2-Aminopyrimidine or 2-Aminiopyridinone Derivatives and Their Use
AU2007261749B2 (en) Substituted isoindoles as bace inhibitors and their use
US20090023762A1 (en) Substituted 2-Aminopyrimidine-4-Ones, Their Pharmaceutical Compositions And Their Use In The Treatment And/Or Prevention Of Ab-Related Pathologies
EP1802587A1 (fr) Composes amino substitues et utilisation de ces compose
US20090099217A1 (en) 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies
WO2007058601A1 (fr) Nouveaux composes 2-amino-imidazole-4-one et leur utilisation dans la fabrication d'un medicament destine a etre utilise dans le traitement d'une deficience cognitive, la maladie d'alzheimer, le neurodegenerescence et la demence
US20090062282A1 (en) Substituted Amino-Pyrimidones and Uses Thereof
WO2009005470A1 (fr) Dérivés d'isoindole substitués aryle et hétéroaryle en tant qu'inhibiteurs de la bace
MX2008005985A (es) Compuestos iv y usos de los mismos

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 3799/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008541108

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12093646

Country of ref document: US

Ref document number: 2006813004

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200680051122.7

Country of ref document: CN